Relapse Rates in Schizophrenia: Monotherapy vs. Polypharmacy
Author Information
Author(s): Millier Aurelie, Sarlon Emmanuelle, Azorin Jean-Michel, Boyer Laurent, Aballea Samuel, Auquier Pascal, Toumi Mondher
Primary Institution: Creativ-Ceutical France
Hypothesis
Does the type of antipsychotic treatment (monotherapy vs. polypharmacy) affect the rate of relapse in schizophrenic patients over a 2-year period?
Conclusion
Antipsychotic polypharmacy is not statistically associated with an increase in relapse after adjusting for propensity scores.
Supporting Evidence
- 50 patients (27.3%) had at least one period of relapse.
- Patients receiving polypharmacy had a higher general psychopathology PANSS subscore.
- Relapse was found in 23.7% of patients given monotherapy and 33.3% given polypharmacy.
Takeaway
This study looked at whether taking one or more antipsychotic medications affects relapse in people with schizophrenia. It found that taking multiple medications didn't lead to more relapses.
Methodology
A multicenter cohort study with a propensity-adjusted analysis over a 2-year period.
Potential Biases
Potential confounding factors due to non-random assignment of treatment.
Limitations
The treatment was not randomly assigned, which may confound results; the sample may not be representative of all schizophrenic patients.
Participant Demographics
70.9% male, mean age 24.8 years.
Statistical Information
P-Value
p = 0.16
Confidence Interval
HR = 1.686 (0.812; 2.505)
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website